Revenue
No reported data
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
Price—Loading quote
Net income
2019
2020
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 · Dec 31 | 2020 · Feb 29 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Research & development | $11.7M | $22.9M | $31.4M | $22.9M | $4.9M | $295,150 | — | — |
| Operating expenses | $20.2M | $30.8M | $39.5M | $28.2M | $10.1M | $2.4M | $724,740 | $152,789 |
| Operating income | −$20.2M | −$30.8M | −$39.5M | −$28.2M | −$10.1M | −$2.4M | −$724,740 | −$152,789 |
| Net income | −$19.9M | −$29.9M | −$39.3M | −$28.3M | −$8.5M | −$3.8M | $617,903 | $574,131 |
| Basic EPSper diluted share | -$5.48 | -$17.73 | -$1.65 | -$1.45 | -$0.58 | -$1.24 | -$0.21 | -$0.04 |
| Diluted EPSper diluted share | — | — | — | — | — | -$1.24 | -$0.21 | -$0.04 |